Language:

Efficacy of bevacizumab in the treatment of refractory brain edema of metastatic tumors from different sources

Neurological research (New York), 2021-12, Vol.43 (12), p.955-960 [Peer Reviewed Journal]

2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 ;ISSN: 0161-6412 ;EISSN: 1743-1328 ;DOI: 10.1080/01616412.2021.1948740 ;PMID: 34766548

Digital Resources/Online E-Resources

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Efficacy of bevacizumab in the treatment of refractory brain edema of metastatic tumors from different sources
Author: Bai, Xuexue ; Zhang, Yuan ; Ding, Weilong ; Wang, Shiyong
Subjects: Adult ; Angiogenesis Inhibitors - therapeutic use ; Bevacizumab ; Bevacizumab - therapeutic use ; Brain Edema - drug therapy ; Brain Edema - etiology ; Brain Neoplasms - complications ; Brain Neoplasms - drug therapy ; Brain Neoplasms - secondary ; breast cancer ; Breast Neoplasms - complications ; Breast Neoplasms - drug therapy ; Breast Neoplasms - secondary ; Female ; Humans ; lung cancer ; Lung Neoplasms - complications ; Lung Neoplasms - drug therapy ; Lung Neoplasms - secondary ; Male ; metastatic tumors ; Middle Aged ; refractory brain edema ; Retrospective Studies
Is Part Of: Neurological research (New York), 2021-12, Vol.43 (12), p.955-960
Description: Aim: This retrospective study investigated bevacizumab in treating refractory brain edema in patients with brain-metastatic tumors from different sources. Methods: From January 2013 to December 2019, 83 patients with brain metastases and refractory brain edema were treated with bevacizumab. They were divided into lung cancer group and breast cancer group. The clinical data, the efficacy, and the side effects of bevacizumab were recorded. Magnetic resonance imaging was performed before and after bevacizumab treatment. The volume of tumor and brain edema were measured respectively. Results: After treatment with bevacizumab, 72 cases of refractory brain edema were significantly relieved. The edema control rate was 93.75% in the lung cancer group and 77.14% in the breast cancer group (P < .05). The brain edema volume was significantly reduced after bevacizumab treatment from 198,286.84 ± 60,564.40 to 114,677.71 ± 42,337.38mm 3 (P < .01), and the edema index was reduced from 26.14 ± 7.24 to 17.18 ± 5.14 (P < .01). Hypertension was observed in 14 cases. Conclusion: Bevacizumab could significantly reduce refractory brain edema with a control rate of 86.75%. The efficacy of bevacizumab in the treatment of refractory brain edema caused by lung cancer is better than that of breast cancer.
Publisher: England: Taylor & Francis
Language: English
Identifier: ISSN: 0161-6412
EISSN: 1743-1328
DOI: 10.1080/01616412.2021.1948740
PMID: 34766548
Source: Taylor & Francis Open Access

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Efficacy of bevacizumab in the treatment of refractory brain edema of metastatic tumors from different sources

2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 ;ISSN: 0161-6412 ;EISSN: 1743-1328 ;DOI: 10.1080/01616412.2021.1948740 ;PMID: 34766548

Searching Remote Databases, Please Wait